The global Myelodysplastic Syndrome Drugs market size was valued at US$ 3.6 billion in 2020 and is anticipated to grow at a CAGR of 11.7% during forecast period 2021 to 2030.
The market is primarily driven by emergence of novel therapeutics. Rising geriatric population, increasing incidence of niche indications, and improving healthcare services are some of the key factors expected to drive the market.
Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in the U.S. annually. An estimated 60,000 people in the U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability and access to novel treatments in major countries provides strong commercial opportunities to the market.
Aging population and growing awareness about the disease are key drivers of this market. Government initiatives to provide target-specific treatments and favorable reimbursement policies are also expected to fuel market growth. The MDS International Foundation is a nonprofit health organization that provides psychological support as well as funding to patients for treatment of the condition.
High cost of therapeutics remains an impediment to the growth of the market for myelodysplastic syndrome drugs. However, affordable healthcare measures are being implemented across all major markets, affecting companies’ pricing strategies and reimbursement scenario. In addition, rising cost-consciousness is projected to hinder premium pricing strategies of companies in the market.
MDS drugs are divided into the following therapeutic classes: hypomethylating agents, immunomodulatory drugs, and anti-anemics. Immunomodulatory drugs held the largest market share in 2016 and is anticipated to retain its dominance through 2022 due to rising adoption of therapeutics and lack of generic competition. Currently, Revlimid (lenalidomide) is the only one approved for treatment of low-risk MDS and myelodysplastic syndrome with isolated del(5q).
Hypomethylating agents such as Celgene’s Vidaza and Otsuka’s Dacogen are used as first-line treatment for patients with high-risk myelodysplastic syndrome. This segment is forecast to witness a steep fall in market share due to patent expirations of both the aforementioned drugs, which has led to the launch of several generics in the market.
The anticipated launch of Celgene’s luspatercept and Amgen’s Aranesp in 2019 are projected to significantly fuel the anti-anemics drug segment. Both are under investigation in late-stage clinical trials for treatment of myelodysplastic syndrome. Recent study outcomes have demonstrated that they successfully increased RBC count in the blood, thus reducing need for frequent blood transfusions.
The U.S. dominated the global myelodysplastic syndrome treatment drugs market with a share of more than 48.0% in 2016, followed by Japan and Germany. Although Japan is projected to exhibit the highest CAGR of nearly 13.0% among the seven major markets, the U.S. is expected to retain its dominant position throughout the forecast period.
Multiple product launches during the forecast period, increased adoption of novel therapies, presence of a large cohort, and high cost of treatment in the U.S. are some of the factors responsible for its dominance. The seven major markets are estimated to collectively expand at a CAGR of 9.4%, while the Rest of the World is projected to register a CAGR of 12.1% during the forecast period.
myelodysplastic syndrome market include Celgene Corporation; Amgen Inc.; Otsuka Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company Limited.
Therapeutic Class Outlook
The Myelodysplastic Syndrome Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Myelodysplastic Syndrome Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Myelodysplastic Syndrome Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myelodysplastic Syndrome Drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Myelodysplastic Syndrome Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Myelodysplastic Syndrome Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Myelodysplastic Syndrome Drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Myelodysplastic Syndrome Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Myelodysplastic Syndrome Drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Myelodysplastic Syndrome Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Myelodysplastic Syndrome Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Myelodysplastic Syndrome Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Myelodysplastic Syndrome Drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Myelodysplastic Syndrome Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Myelodysplastic Syndrome Drugs market. These factors have benefited the growth of the global market for Myelodysplastic Syndrome Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Myelodysplastic Syndrome Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Myelodysplastic Syndrome Drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Pulmonary Arterial Hypertension Market (By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators; By Type: Branded, Generics; By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Mechanical Ventilator Market (By Product: Critical Care, Neonatal, Transport & Portable; By Ventilation Mode: Invasive, Non-invasive; By End-use: Hospitals, Home Healthcare) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Surgical display Market (By Type: Low-end, Mid-end, High-end) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Agrochemicals Market (By Product: Fertilizer, Crop Protection Chemicals, Plant Growth Regulators; By Application: Cereal & Grains, Oilseeds & Pulses, Fruits & Vegetables) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Home Infusion Therapy Market (By Product: Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors; By Application: Anti-infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...